Spero Therapeutics, Inc. SPRO
Biotechnology: Pharmaceutical Preparations · IPO 2017 · data as of November 13, 2026
Spero Therapeutics, Inc. (SPRO) is a healthcare company listed in the US with a market value of about $58M. In the twelve months to September 30, 2026 it had revenue of $42M and net income of -$30M, a net margin of -71.0%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 48% a year, a 5-year average ROIC of -52%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 30% below the current price.
About Spero Therapeutics
Spero Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2017. Revenue went from $335000 in 2016 to $67M in 2025, growth of about 80.1% a year. It was profitable in 3 of the last 10 years in our data. Its share count rose by 57% over three years (dilution for shareholders). It spends 58% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $42M | $67M | $48M | $104M | $54M | $18M | $9M | $18M | $4M | $2M | $335000 |
| Net income | -$30M | $9M | -$69M | $23M | $46M | -$90M | -$78M | -$61M | -$42M | -$39M | -$25M |
| Free cash flow | — | — | — | — | — | — | -$86M | -$50M | -$42M | -$39M | -$30M |
| EPS (diluted) | $-0.49 | $0.15 | $-1.27 | $0.43 | $-1.23 | $-2.91 | $-3.52 | $-3.35 | $-2.60 | $-17.82 | $-95.87 |
| Net margin | -71.0% | 12.8% | -142.9% | 22.0% | 86.7% | -491.9% | -839.2% | -335.6% | -1051.4% | -1957.7% | -7609.2% |
| ROIC | — | 9.9% | -145.5% | 17.1% | -51.0% | -91.9% | -56.5% | -78.7% | -37.1% | -49.3% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $5.33, 433% above the current price; targets range from $4.00 to $6.00; the consensus rating is “Buy”; expected EPS is $-1.28 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Spero Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 30% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Spero Therapeutics pay a dividend?
Not currently.
Is Spero Therapeutics a good stock to buy?
We do not give buy or sell advice. Spero Therapeutics scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.